^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
spanlecortemlocel (MGTA-456)
i
Other names: expanded umbilical cord blood product HSC835, MGTA 456, MGTA-456, HSC-835, HSC835, LFU835-expanded umbilical cord blood hematopoietic stem cells
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Dianthus Therap
Drug class:
Cell therapy
Related drugs:
2ms
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (clinicaltrials.gov)
P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Jun 2024 --> Jun 2025
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • spanlecortemlocel (MGTA-456)
over1year
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (clinicaltrials.gov)
P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Apr 2023 --> Jun 2024
Trial completion date
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • spanlecortemlocel (MGTA-456)
2years
Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy (clinicaltrials.gov)
P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Trial completion date: Aug 2023 --> Apr 2023 | Trial primary completion date: Jul 2023 --> Mar 2023
Trial completion date • Trial primary completion date
|
FLT3 (Fms-related tyrosine kinase 3) • NPM1 (Nucleophosmin 1) • KMT2A (Lysine Methyltransferase 2A) • HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1) • CEBPA (CCAAT Enhancer Binding Protein Alpha)
|
FLT3-ITD mutation • NPM1 mutation • MLL rearrangement • MLL rearrangement • CEBPA mutation • FLT3 wild-type
|
cyclophosphamide • melphalan • fludarabine IV • busulfan • spanlecortemlocel (MGTA-456)
Share via
